ClinicalTrials.gg
CompletedNCT06002217TAP ALIFUpdated Jul 10, 2026

Echo-guided Transverse Abdominal Plane Block (TAP) in Anterior Lumbar Arthrodesis (ALIF)

An interventional study of Levobupivacaine and Placebo Tap block in Fusion of Spine, Lumbar Region, sponsored by Clinique Saint Jean, France. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Clinique Saint Jean, France · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this interventional study is to is to compare the effect of a tap block versus a placebo in patients undergoing anterior lumbar spine surgery.

The main question it aims to answer :

  • whether tap block can reduce the need for postoperative pain medication Participants will be randomized into two groups and all postoperative pain medication will be recorded over 3 days.

Researchers will compare tap block vs placebo to see if it reduces postoperative pain.

02

Conditions studied

  • Fusion of Spine, Lumbar Region
03

In context

Lead sponsor

Clinique Saint Jean, France is the lead sponsor of 15 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient affiliated or entitled to a social security plan.

  • Patient who has been informed about the study and has co-signed a consent form with the investigator. consent to participate in the study.
  • Patients over 18 years of age scheduled for abdominal disc surgery on one or two levels.
  • Patient with ASA criteria 1, 2 and 3.

Exclusion criteria

Exclusion Criteria:

  • Patients with intolerance or to paracetamol, anti-inflammatory or morphine.
  • Patients allergic to local anesthetics.
  • Pregnant or breast-feeding patient.
  • patient undergoing cancer or trauma surgery trauma.
  • Patient participating in another interventional study.
  • Patient with a history of lumbar arthrodesis.
  • Patient refusing to sign consent form.
  • Patient unable to give .
  • Patient under court protection, guardianship or trusteeship.
  • Patient not available for study follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    TAP Block

    Drug: Levobupivacaine

  • Placebo comparator
    saline solution

    Other: Placebo Tap block

Interventions

  • Patients in the tap block arm will receive an injection of levobupivacaine 2.5mg/ml

  • OtherPlacebo Tap block

    Patients in the placebo arm will receive an injection of salin solution 2.5mg/ml , in the same way as tap block

06

What researchers measure

Primary outcomes

  1. Analgesic consumption

    The use of analgesics (oral or venous) during the during the 72 hours following surgery

    Time frame: 72hours

Secondary outcomes

  1. Pain assessment will be reported for 72 hours after surgery measured on a Visual analogue scale between 0 and 10

    Pain assessment for 72 hours after surgery, measured on a scale between 0 and 10 (VAS scale ), where 0 is no pain and 10 is maximum pain

    Time frame: 72hours

07

Study locations

1 site
  • Clinique St jean sud de france
    Montpellier, 34430, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jul 2026, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 21, 2023
StartActual
Feb 5, 2024
Primary completionActual
Jul 9, 2026
CompletionActual
Jul 9, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06002217
Lead sponsor
Clinique Saint Jean, France
Responsible party
Guillaume LONJON (Principal investigator, Clinique Saint Jean, France) — Principal investigator
First posted
Aug 21, 2023
Start date
Feb 5, 2024
Primary completion
Jul 9, 2026
Completion
Jul 9, 2026
Last update
Jul 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levobupivacaine

Start the discussion